17 results on '"Mlisana, Koleka P."'
Search Results
2. Mobile genetic elements-mediated Enterobacterales-associated carbapenemase antibiotic resistance genes propagation between the environment and humans: A One Health South African study.
- Author
-
Ramsamy, Yogandree, Mlisana, Koleka P., Amoako, Daniel G., Abia, Akebe Luther King, Ismail, Arshad, Allam, Mushal, Mbanga, Joshua, Singh, Ravesh, and Essack, Sabiha Y.
- Published
- 2022
- Full Text
- View/download PDF
3. Patients' readiness to start highly active antiretroviral treatment for HIV.
- Author
-
Gebrekristos, Hirut T., Mlisana, Koleka P., and Karim, Quarraisha Abdool
- Subjects
- *
ANTIRETROVIRAL agents , *HIV , *EPIDEMICS , *PATIENTS - Abstract
Reports on the growth of initiatives to increase access to antiretroviral treatment in resource constrained settings, despite the operational and ethical challenges presented by the scale and magnitude of the HIV epidemic in Africa. Revelation that no clarity or consensus exists on what constitutes patients' readiness for HIV treatment and how that readiness should be addressed; View that the more established and readily measurable criteria currently used in decisions to start highly active antiretroviral treatment need to be expanded.
- Published
- 2005
- Full Text
- View/download PDF
4. Consequences of rpoB mutations missed by the GenoType MTBDR plus assay in a programmatic setting in South Africa.
- Author
-
Mvelase, Nomonde R., Cele, Lindiwe P., Singh, Ravesh, Naidoo, Yeshnee, Giandhari, Jennifer, Wilkinson, Eduan, de Oliveira, Tulio, Swe-Han, Khine Swe, and Mlisana, Koleka P.
- Subjects
- *
ANTITUBERCULAR agents , *WHOLE genome sequencing , *GENOTYPES , *GENETIC mutation , *ISONIAZID , *CONTACT tracing - Abstract
Background: Rifampicin resistance missed by commercial rapid molecular assays but detected by phenotypic assays may lead to discordant susceptibility results and affect patient management. Objective: This study was conducted to evaluate the causes of rifampicin resistance missed by the GenoType MTBDR plus and its impact on the programmatic management of tuberculosis in KwaZulu-Natal, South Africa. Methods: We analysed routine tuberculosis programme data from January 2014 to December 2014 on isolates showing rifampicin susceptibility on the GenoType MTBDR plus assay but resistance on the phenotypic agar proportion method. Whole-genome sequencing was performed on a subset of these isolates. Results: Out of 505 patients with isoniazid mono-resistant tuberculosis on the MTBDR plus , 145 (28.7%) isolates showed both isoniazid and rifampicin resistance on the phenotypic assay. The mean time from MTBDR plus results to initiation of drug-resistant tuberculosis therapy was 93.7 days. 65.7% of the patients had received previous tuberculosis treatment. The most common mutations detected in the 36 sequenced isolates were I491F (16; 44.4%) and L452P (12; 33.3%). Among the 36 isolates, resistance to other anti-tuberculosis drugs was 69.4% for pyrazinamide, 83.3% for ethambutol, 69.4% for streptomycin, and 50% for ethionamide. Conclusion: Missed rifampicin resistance was mostly due to the I491F mutation located outside the MTBDR plus detection area and the L452P mutation, which was not included in the initial version 2 of the MTBDR plus. This led to substantial delays in the initiation of appropriate therapy. The previous tuberculosis treatment history and the high level of resistance to other anti-tuberculosis drugs suggest an accumulation of resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Assessment of Antibiotic Resistance and Efflux Pump Gene Expression in Neisseria Gonorrhoeae Isolates from South Africa by Quantitative Real-Time PCR and Regression Analysis.
- Author
-
Mitchev, Nireshni, Singh, Ravesh, Ramsuran, Veron, Ismail, Arshad, Allam, Mushal, Kwenda, Stanford, Mnyameni, Florah, Garrett, Nigel, Swe Swe-Han, Khine, Niehaus, Abraham J., and Mlisana, Koleka P.
- Subjects
- *
NEISSERIA gonorrhoeae , *GENE expression , *REGRESSION analysis , *ANTIMICROBIAL stewardship , *PATIENTS - Abstract
Introduction. Treatment of gonorrhoea infection is limited by the increasing prevalence of multidrug-resistant strains. Cost-effective molecular diagnostic tests can guide effective antimicrobial stewardship. The aim of this study was to correlate mRNA expression levels in Neisseria gonorrhoeae antibiotic target genes and efflux pump genes to antibiotic resistance in our population. Methods. This study investigated the expression profile of antibiotic resistance-associated genes (penA, ponA, pilQ, mtrR, mtrA, mtrF, gyrA, parC, parE, rpsJ, 16S rRNA, and 23S rRNA) and efflux pump genes (macAB, norM, and mtrCDE), by quantitative real-time PCR, in clinical isolates from KwaZulu-Natal, South Africa. Whole-genome sequencing was used to determine the presence or absence of mutations. Results. N. gonorrhoeae isolates, from female and male patients presenting for care at clinics in KwaZulu-Natal, South Africa, were analysed. As determined by binomial regression and ROC analysis, the most significant (p ≤ 0.05) markers for resistance prediction in this population, and their cutoff values, were determined to be mtrC (p = 0.024 ; cutoff <0.089), gyrA (p = 0.027 ; cutoff <0.0518), parE (p = 0.036 ; cutoff <0.0033), rpsJ (p = 0.047 ; cutoff <0.0012), and 23S rRNA (p = 0.042 ; cutoff >7.754). Conclusion. Antimicrobial stewardship includes exploring options to conserve currently available drugs for gonorrhoea treatment. There is the potential to predict an isolate as either susceptible or nonsusceptible based on the mRNA expression level of specific candidate markers, to inform patient management. This real-time qPCR approach, with few targets, can be further investigated for use as a potentially cost-effective diagnostic tool to detect resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Persistent Hepatitis B Viraemia with Polymerase Mutations among HIV/HBV Co-Infected Patients on HBV-Active ART in KwaZulu-Natal, South Africa.
- Author
-
Msomi, Nokukhanya, Parboosing, Raveen, Wilkinson, Eduan, Giandhari, Jennifer, Govender, Kerusha, Chimukangara, Benjamin, and Mlisana, Koleka P.
- Subjects
- *
HEPATITIS B virus , *HEPATITIS B , *VIREMIA , *LOGISTIC regression analysis , *HIV , *NUCLEOTIDE sequencing - Abstract
To understand the problem of persistent Hepatitis B virus (HBV) viraemia in HIV/HBV co-infected patients on HBV-active antiretroviral therapy (ART), we assessed the rate of HBV virological response in patients on HBV-active ART in KwaZulu-Natal, South Africa, and analysed factors associated with persistent HBV viraemia. One hundred and fifty eligible participants with a chronic HBV diagnosis, with or without HIV coinfection, were enrolled and followed up after 6 months. The HBV pol gene was sequenced by next-generation sequencing and mutations were determined using the Stanford HBVseq database. Logistic regression analysis was used to assess factors associated with HBV viraemia at 6-month follow-up. The mean duration of HBV-active ART was 24 months. Thirty-seven of one hundred and six (35%) participants receiving HBV-active ART for longer than 6 months had virological failure. Advanced immunosuppression with CD4+ cell counts <200 cells/μL was independently associated with persistent HBV viraemia, aOR 5.276 (95% CI 1.575–17.670) p = 0.007. A high proportion of patients on HBV-active ART are unsuppressed, which will ultimately have an impact on global elimination goals. Better monitoring should be implemented, especially in HIV-coinfected patients with low CD4+ cell counts and followed by early HBV drug-resistance testing. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. High-Resolution Melting Analysis to Detect Antimicrobial Resistance Determinants in South African Neisseria gonorrhoeae Clinical Isolates and Specimens.
- Author
-
Mitchev, Nireshni, Singh, Ravesh, Ramsuran, Veron, Ismail, Arshad, Allam, Mushal, Kwenda, Stanford, Mnyameni, Florah, Garrett, Nigel, Swe-Han, Khine Swe, Niehaus, Abraham J., and Mlisana, Koleka P.
- Subjects
- *
NEISSERIA gonorrhoeae , *DRUG resistance in microorganisms , *MICROBIAL sensitivity tests , *SOUTH Africans , *SINGLE nucleotide polymorphisms , *NEISSERIA , *SEXUALLY transmitted diseases , *PLASMID genetics - Abstract
Background. Antimicrobial resistance is limiting treatment options for Neisseria gonorrhoeae infections. To aid or replace culture and the syndromic management approach, molecular assays are required for antimicrobial susceptibility testing to guide appropriate and rapid treatment. Objective. We aimed to detect single-nucleotide polymorphisms and plasmids associated with antimicrobial resistance from N. gonorrhoeae isolates from a clinic population in South Africa, using real-time PCR as a rapid test for AMR detection. Methods. N. gonorrhoeae isolates, from female and male patients presenting for care at a sexually transmitted infections clinic in Durban, South Africa, were analysed using phenotypic and genotypic methods for identification and antibiotic susceptibility testing (AST). Real-time PCR and high-resolution melting analysis were used to detect porA pseudogene (species-specific marker) and resistance-associated targets. Whole-genome sequencing was used as the gold standard for the presence of point mutations. Results. The real-time porA pseudogene assay identified all N. gonorrhoeae-positive isolates and specimens. Concordance between molecular detection (real-time PCR and HRM) and resistance phenotype was ≥92% for blaTEM (HLR penicillin), rpsJ_V57M (tetracycline), tetM (tetracycline), and gyrA_S91F (ciprofloxacin). Resistance determinants 16SrRNA_C1192U (spectinomycin), mtrR_G45D (azithromycin), and penA_D545S, penA_mosaic (cefixime/ceftriaxone) correlated with the WHO control isolates. Conclusions. Eight resistance-associated targets correlated with phenotypic culture results. The porA pseudogene reliably detected N. gonorrhoeae. Larger cohorts are required to validate the utility of these targets as a convenient culture-free diagnostic tool, to guide STI management in a South African population. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Performance of TaqMan probes for the detection of sexually transmitted infections in South African women.
- Author
-
Mitchev, Nireshni, Singh, Ravesh, Garrett, Nigel, Ramsuran, Veron, Niehaus, Abraham J., and Mlisana, Koleka P.
- Subjects
- *
SOUTH Africans , *SEXUALLY transmitted diseases , *NEISSERIA gonorrhoeae , *CHLAMYDIA trachomatis , *VAGINAL discharge , *POLYMERASE chain reaction , *MYCOPLASMA , *ZIKA virus - Abstract
Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis and Mycoplasma genitalium are the four main aetiologies of sexually transmitted infections responsible for vaginal discharge syndrome (VDS). Commercially available multiplex polymerase chain reaction (PCR) assays are expensive and generally not customisable. We evaluated a highly customisable singleplex PCR approach by testing it in parallel with the Anyplex™ II STI-7 detection assay in a cohort of South African women that presented with VDS between May 2016 and January 2017. Our multiple singleplex PCR strategy proved to be a simple, accurate, rapid, affordable and scalable option for diagnosing VDS. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Design and synthesis of novel heterofused pyrimidine analogues as effective antimicrobial agents.
- Author
-
Chandrasekaran, Balakumar, Cherukupalli, Srinivasulu, Karunanidhi, Sivanandhan, Kajee, Afsana, Aleti, Rajeshwar Reddy, Sayyad, Nisar, Kushwaha, Babita, Merugu, Srinivas Reddy, Mlisana, Koleka P., and Karpoormath, Rajshekhar
- Subjects
- *
PYRIMIDINE synthesis , *ANTI-infective agents , *ANTITUBERCULAR agents , *NUCLEAR magnetic resonance spectroscopy , *DRUG design - Abstract
Abstract A total of 66 novel heterofused pyrimidine analogues (pyrazolo[3,4- d ]pyrimidine (7 - 43) and pyrido[2,3- d ]pyrimidine (51a - l & 52a - h)) were synthesized by employing suitable methods. The desired structures of all the synthesized compounds were confirmed based on FT-IR, 1H NMR, 13C NMR and HRMS experimental data. Further, 19F NMR and 1H-15N HMBC of the representative compound were presented. All the final compounds were screened for their in vitro antitubercular (Mycobacterium tuberculosis ; H 37 Rv), antibacterial (S. aureus , B. subtilis , E. coli and P. aeruginosa) and antifungal (C. neoformans, C. albicans and A. niger) activities. Compounds 51d , 51j , 51k , 51l , and 51g displayed good antibacterial and antifungal activity (MIC = 12.5 μg/ml) against bacterial and fungal strains, while moderate inhibition (MIC = 59 μM) was observed for 51l against H 37 Rv strain. Graphical abstract Image 1 Highlights • 66 Novel fused pyrimidines were synthesized and characterized. • In vitro anti-tubercular, anti-bacterial and anti-fungal screening were conducted. • Fluorinated pyrimidines 51d , 51j , 51k , 51l , and 51g showed significant antimicrobial activities. • Compound 51l displayed good anti-tubercular activity against H 37 Rv strain. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Antimicrobial stewardship in South Africa: a fruitful endeavour.
- Author
-
Ramsamy, Yogandree, Muckart, David J J, and Mlisana, Koleka P
- Subjects
- *
ANTI-infective agents , *COMMUNICABLE diseases , *CROSS-sectional method , *RANDOMIZED controlled trials , *MICROBIOLOGY - Published
- 2016
- Full Text
- View/download PDF
11. Novel imidazo[2,1-b]-1,3,4-thiadiazoles as promising antifungal agents against clinical isolate of Cryptococcus neoformans.
- Author
-
Alwan, Wesam S., Karpoormath, Rajshekhar, Palkar, Mahesh B., Patel, Harun M., Rane, Rajesh A., Shaikh, Mahamadhanif S., Kajee, Afsana, and Mlisana, Koleka P.
- Subjects
- *
CRYPTOCOCCUS neoformans , *CRYPTOCOCCUS , *ANTI-infective agents , *CANDIDA albicans , *ANTIFUNGAL agents - Abstract
We herein report the synthesis and in vitro antimicrobial evaluation of twenty five novel hybrid derivatives of imidazo [2,1- b ]-1,3,4-thiadiazole containing chalcones ( 5a – o ) and Schiff bases ( 6a – j ) against three fungal strains ( Candida albicans , Cryptococcus neoformans and Aspergillus niger ). Most of the tested compounds displayed substantial anti-fungal activity with MICs ranging between 1.56 and 100 μg/mL. Compounds 5a , 5b and 5n exhibited promising activity against C. neoformans at a MIC 1.56 μg/mL. In addition, compound 5n also demonstrated significant antifungal activity against the clinical isolates of C. neoformans at MIC 3.125 μg/mL. However, moderate activity was observed for these compounds against four bacterial strains ( Staphylococcus aureus , Bacillus subtilis , Escherichia coli and Pseudomonas aeruginosa ) and Mycobacterium tuberculosis (H 37 Rv). [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Effects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa.
- Author
-
Dlamini-Mvelase, Nomonde R., Werner, Lise, Phili, Rogerio, Cele, Lindiwe P., and Mlisana, Koleka P.
- Abstract
Background: An algorithm instituted following Xpert MTB/RIF (Xpert) introduction in South Africa advocates for treating all Xpert rifampicin resistant patients as MDR-TB cases while awaiting confirmation by phenotypic or genotypic drug susceptibility testing. This study evaluates how the Xpert has influenced the diagnosis and management of drug resistant TB in the highest burdened district of KwaZulu-Natal Province. Methods: Data was retrospectively collected from all patients with rifampicin resistance on Xpert performed between March 2011 and April 2012. Xpert results were compared with those of phenotypic and/genotypic drug susceptibility testing. Patients’ records were used to determine the time to treatment initiation. Results: Out of 637 patients tested by Xpert, 50% had confirmatory results, of which a third were sent on the same day as Xpert test. The rate of rifampicin discordance and monoresistance was 8.8% and 13.4% respectively and there was no difference between phenotypic and genotypic confirmation. Among those who had been initiated on treatment, 28%, 40%, 21% and 8% of patients commenced within 2 weeks, 1 month, 2 months and 3 months of Xpert testing respectively, while the remaining 3% were observed without treatment. Conclusion: This study emphasizes the importance of complying with the algorithm in confirming all Xpert rif resistant cases so as to ensure proper management of these patients. Despite the rapidity of the Xpert results, only about 70% of patients had been initiated treatment at one month. Therefore there is a definite need to improve the health systems in order to improve on these delays. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. Co-enrollment in multiple HIV prevention trials — Experiences from the CAPRISA 004 Tenofovir gel trial
- Author
-
Karim, Quarraisha Abdool, Kharsany, Ayesha B.M., Naidoo, Kasavan, Yende, Nonhlanhla, Gengiah, Tanuja, Omar, Zaheen, Arulappan, Natasha, Mlisana, Koleka P., Luthuli, Londiwe R., and Karim, Salim S. Abdool
- Subjects
- *
AIDS prevention , *CLINICAL trials , *YOUNG women , *FOLLOW-up studies (Medicine) , *POPULATION health , *POPULATION research , *MEDICAL research methodology - Abstract
Abstract: Background: In settings where multiple HIV prevention trials are conducted in close proximity, trial participants may attempt to enroll in more than one trial simultaneously. Co-enrollment impacts on participant''s safety and validity of trial results. We describe our experience, remedial action taken, inter-organizational collaboration and lessons learnt following the identification of co-enrolled participants. Experiences: Between February and April 2008, we identified 185 of the 398 enrolled participants as ineligible. In violation of the study protocol exclusion criteria, there was simultaneous enrollment in another HIV prevention trial (ineligible co-enrolled, n=135), and enrollment of women who had participated in a microbicide trial within the past 12months (ineligible not co-enrolled, n=50). Following a complete audit of all enrolled participants, ineligible participants were discontinued via study exit visits from trial follow-up. Custom-designed education program on co-enrollment impacting on participants'' safety and validity of the trial results was implemented. Shared electronic database between research units was established to enable verification of each volunteer''s trial participation and to prevent future co-enrollments. Lessons learnt: Interviews with ineligible enrolled women revealed that high-quality care, financial incentives, altruistic motives, preference for sex with gel, wanting to increase their likelihood of receiving active gel, perceived low risk of discovery and peer pressure are the reasons for their enrollment in the CAPRISA 004 trial. Conclusion: Instituting education programs based on the reasons reported by women for seeking enrollment in more than one trial and using a shared central database system to identify co-enrollments have effectively prevented further co-enrollments. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
14. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
- Author
-
Karim, Quarraisha Abdool, Kharsany, Ayesha B. M., Frohlich, Janet A., Baxter, Cheryl, Yende, Nonhlanhla, Mansoor, Leila E., Mlisana, Koleka P., Maarschalk, Silvia, Arulappan, Natasha, Grobler, Anneke, Sibeko, Sengeziwe, Omar, Zaheen, Gengiah, Tanuja N., Mlotshwa, Mukelisiwe, Samsunder, Natasha, and Karim, Salim S. Abdool
- Subjects
- *
HIV-positive women , *HIV infections , *MONOGAMOUS relationships , *CONDOM use - Abstract
Background: Young women in sub-Saharan Africa bear a disproportionate burden of HIV infection compared to men but have limited options to reduce their HIV risk. Microbicides could fill an important HIV prevention gap for sexually active women who are unable to successfully negotiate mutual monogamy or condom use. Purpose: This paper describes the baseline sample characteristics in the CAPRISA 004 trial which assessed the safety and effectiveness of the vaginal microbicide, 1% tenofovir gel for HIV prevention in South Africa. Methods: This analysis assessed the baseline demographic, clinical and sexual behavior data of women screened and enrolled into the trial. The characteristics were summarized using descriptive summary measures; expressed as means and percent for categorical variables. Results: HIV prevalence at screening was 25.8% [95% Confidence Interval (CI):23.9-27.7). Of the 889 eligibly enrolled women who contributed follow-up data, rural participants recruited from a family planning (FP) clinic were younger, more likely to be living apart from their regular partner, reported lower coital frequency, had lower condom use (p < 0.001). In contrast, urban participants recruited from a sexually transmitted disease (STD) clinic reported higher numbers of lifetime sexual partners, new partners in the last 30 days and receiving money in exchange for sex (p < 0.001). [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
15. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women.
- Author
-
Abdool Karim, Quarraisha, Abdool Karim, Salim S., Frohlich, Janet A., Grobler, Anneke C., Baxter, Cheryl, Mansoor, Leila E., Kharsany, Ayesha B. M., Sibeko, Sengeziwe, Mlisana, Koleka P., Omar, Zaheen, Gengiah, Tanuja N., Maarschalk, Silvia, Arulappan, Natasha, Mlotshwa, Mukelisiwe, Morris, Lynn, and Taylor, Douglas
- Subjects
- *
CLINICAL drug trials , *ANTIRETROVIRAL agents , *HIV prevention , *RESEARCH methodology , *BLIND experiment , *RANDOMIZED controlled trials , *PLACEBOS , *AIDS in women - Abstract
The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the prevention of HIV acquisition in women. A double-blind, randomized controlled trial was conducted comparing tenofovir gel (n = 445 women) with placebo gel (n = 444 women) in sexually active, HIV-uninfected 18- to 40-year-old women in urban and rural KwaZulu-Natal, South Africa. HIV serostatus, safety, sexual behavior, and gel and condom use were assessed at monthly follow-up visits for 30 months. HIV incidence in the tenofovir gel arm was 5.6 per 100 women-years (person time of study observation) (38 out of 680.6 women-years) compared with 9.1 per 100 women-years (60 out of 660.7 women-years) in the placebo gel arm (incidence rate ratio = 0.61; P = 0.017). In high adherers (gel adherence > 80%), HIV incidence was 54% lower (P = 0.025) in the tenofovir gel arm. In intermediate adherers (gel adherence 50 to 80%) and low adherers (gel adherence < 50%), the HIV incidence reduction was 38 and 28%, respectively. Tenofovir gel reduced HIV acquisition by an estimated 39% overall, and by 54% in women with high gel adherence. No increase in the overall adverse event rates was observed. There were no changes in viral load and no tenofovir resistance in HIV seroconverters. Tenofovir gel could potentially fill an important HIV prevention gap, especially for women unable to successfully negotiate mutual monogamy or condom use. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
16. rpoB Mutations Causing Discordant Rifampicin Susceptibility in Mycobacterium tuberculosis : Retrospective Analysis of Prevalence, Phenotypic, Genotypic, and Treatment Outcomes.
- Author
-
Mvelase, Nomonde R, Pillay, Melendhran, Sibanda, Wilbert, Ngozo, Jacqueline N, Brust, James C M, and Mlisana, Koleka P
- Subjects
- *
MYCOBACTERIUM tuberculosis , *TREATMENT effectiveness , *RIFAMPIN , *DISEASE prevalence - Published
- 2019
- Full Text
- View/download PDF
17. Antibiotic resistance trends of ESKAPE pathogens in Kwazulu-Natal, South Africa: A five-year retrospective analysis.
- Author
-
Ramsamy, Yogandree, Essack, Sabiha Y., Sartorius, Benn, Patel, Miriam, and Mlisana, Koleka P.
- Subjects
- *
ANTIBIOTICS , *ANTI-infective agents , *DISEASE susceptibility , *DRUG resistance in bacteria - Abstract
Background To combat antimicrobial resistance, the World Health Organization developed a global priority pathogen list of antibiotic-resistant bacteria for prioritisation of research and development of new, effective antibiotics. Objective This study describes a five-year resistance trend analysis of the ESKAPE pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp., from Kwazulu-Natal, South Africa. Methods This retrospective study used National Health Laboratory Services data on 64 502 ESKAPE organisms isolated between 2011 and 2015. Susceptibility trends were ascertained from minimum inhibitory concentrations and interpreted using Clinical and Laboratory Standards Institute guidelines. Results S. aureus was most frequently isolated (n = 24, 495, 38%), followed by K. pneumoniae (n = 14, 282, 22%). Decreasing rates of methicillin-resistant S. aureus (28% to 18%, p < 0.001) and increasing rates of extended spectrum beta-lactamase producing K. pneumoniae (54% to 65% p < 0.001) were observed. Carbapenem resistance among K. pneumoniae and Enterobacter spp. was less than 6% during 2011–2014, but increased from 4% in 2014 to 16% in 2015 (p < 0.001) among K. pneumoniae. P. aeruginosa increased (p = 0.002), but resistance to anti-pseudomonal antimicrobials decreased from 2013 to 2015. High rates of multi-drug resistance were observed in A. baumanni (> 70%). Conclusion This study describes the magnitude of antimicrobial resistance in KwaZulu-Natal and provides a South African perspective on antimicrobial resistance in the global priority pathogen list, signalling the need for initiation or enhancement of antimicrobial stewardship and infection control measures locally. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.